-
Review of Skycovion COVID-19 vaccine started
Review of Skycovion COVID-19 vaccine started
-
Review of Skycovion COVID-19 vaccine started
Review of Skycovion COVID-19 vaccine started
EMA’s human medicines committee (CHMP) is reviewing a conditional marketing authorisation application for Skycovion, a vaccine to protect against COVID-19
-
Call for companies to register their i-SPOC
Call for companies to register their i-SPOC
-
Call for companies to register their i-SPOC
Call for companies to register their i-SPOC
Marketing authorisation holders are invited to register their Industry Single Point of Contact on shortages in EMA’s IRIS platform. Deadline for registration is 2 September 2022
-
EMA’s response to monkeypox
EMA’s response to monkeypox
-
EMA’s response to monkeypox
EMA’s response to monkeypox
Declaration of public health emergency triggers a series of new actions for a coordinated response
-
EMA and ECDC update on COVID-19 booster doses
EMA and ECDC update on COVID-19 booster doses
-
EMA and ECDC update on COVID-19 booster doses
EMA and ECDC update on COVID-19 booster doses
The two EU agencies recommended considering second boosters of mRNA vaccines in people aged 60 to 79 and those at risk of severe disease
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal